Top-line data from a Phase 3 clinical trial testing IPX-203 showed Amneal Pharmaceuticals’ carbidopa-levodopa (CD/LD) extended-release capsules work better than immediate-release tablets at reducing “off” time in people with advanced Parkinson’s disease and motor fluctuations. These benefits were observed even when IPX-203 was taken two times less…
Shape Therapeutics and Roche have entered into a strategic collaboration and license agreement to develop RNA-based gene therapies for Parkinson’s, Alzheimer’s, and rare diseases. Under the terms of the agreement, Shape will use its proprietary RNA technologies to leverage molecular machinery already present in human cells to…
PINK1 and Parkin — two proteins whose deficiency has been linked to early-onset Parkinson’s — are involved in the degradation and recycling of mitochondria in neurons, a study shows. While these proteins were known to contribute to mitochondrial recycling in other cell types, this study provides a closer look into mitochondria’s…
The Parkinson’s Foundation announced it will invest $4.3 million in 29 grants for projects that will investigate the underlying causes of Parkinson’s disease and its biological mechanisms, with the goal of finding new treatments. This investment is in addition to the $10 million the Foundation committed to spend earlier this year. “The…
Due in large part to a $15 million Norton Healthcare Foundation investment, the Norton Neuroscience Institute (NNI) has expanded to offer state-of-the-art technologies and enhanced amenities for people with Parkinson’s and other neurological diseases. The newly opened center at the Louisville, Kentucky-based nonprofit institute, which serves its regional community,…
An almost €2 million (about $2.3 million) EU-funded project is advancing the understanding of how damaged or abnormal cell parts are removed at the synapses, a process known as synapse-specific autophagy, and how defects in this mechanism contribute to neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s. Synapses,…
Among people with Parkinson’s disease, those with low blood levels of uric acid — a natural antioxidant — tend to have more severe non-motor symptoms like anxiety, depression, and cognitive dysfunction, a study indicates. It also showed a link between uric acid levels and gray matter volume in the…
Lower levels of dopamine transporter protein in the striatum — a brain region affected significantly in Parkinson’s — may predict the development of the neurodegenerative disease up to eight years earlier in older adults carrying the most common genetic risk factor, a small study suggests. However, the observed variability…
A non-invasive test that measures signals from the olfactory bulb — the part of the brain responsible for scent-perception — may aid in the early diagnosis of Parkinson’s disease, according to a recent study. The test, called an electrobulbogram, also also can inform about disease duration, severity, and the…
Electrical stimulation given through the scalp to a brain region called the supplementary motor area may ease certain aspects of upper limb bradykinesia in people with Parkinson’s disease, a small study suggests. The study, “Transcranial direct current stimulation of supplementary motor area improves upper limb kinematics…
Get regular updates to your inbox.
